Expression of SerpinB3, a member of serine-protease inhibitor family, is associated with the carcinogenesis process as it determines resistance to apoptosis, induces cell proliferation and greater cell invasiveness. Furthermore, it leads to impaired immune surveillance and reduced chemosensitivity.
Recent studies have documented that SerpinB3 is expressed in primary liver tumors with poor prognosis, in more advanced stage of colon and pancreatic tumors, in tumors of the lung, esophagus, breast and ovary with poor response to chemotherapy, thus is a good candidate for targeted cancer therapy.
At present, compounds that are effective at reducing the expression of SerpinB3 in said tumor forms, are lacking.
The 1-piperidin propionic acid, inhibitor of SerpinB3 production, is proposed as a novel adjuvant drug in the treatment of different types of solid tumors overexpressing SerpinB3 and resistant to chemotherapy.

TRL

Lead Optimization/Preclinical

Inventors

Patrizia
Pontisso

Alessandra
Biasiolo

Andrea
Martini

Santina
Quarta

Mariagrazia
Ruvoletto

Cristian
Turato

Gianmarco
Villano

Download the brochure

  • Therapeutic factors for the treatment of PolyQ diseases

    The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, at least nine polyQ disorders have been described, see bellow for a list.[...]

  • Therapeutic use of redox cyclers in diseases linked to mitochondrial respiratory chain dysfunction

    Mitochondrial disorders are debilitating and life-threatening diseases that still lack effective treatment. They are due to genetic defects affecting oxidative phosphorylation, thus mitochondrial fitness and ATP production. Patients with complex III dysfunction develop progressive neurological impairment, myopathy and meet an[...]

  • Novel treatment to mitigate the Ectrodactyly-Ectodermal dysplasia- Clefting (EEC) associated blindness

    The Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome is a rare genetic disorder due to mutations in the p63 gene and characterized by limb defects, orofacial clefting, ectodermal dysplasia, and ocular surface defects that lead to the loss of vision. Currently no specific[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation